In line with this, a recent publication of the AUGMENT-101 trial (ClinicalTrials.gov identifier: NCT04065399) that evaluates the menin inhibitor Revumenib in KMT2A-rearranged relapsed/refractory AML [9] reported the response rate of this compound in a limited number of patients with the most frequent KMT2A translocations. This evidence concerns the gene KMT2A and acute myeloid leukemia.